Long-term results in non randomized patients with acute myelogenous leukemia: A single institution experience

G. L. Deliliers, C. Annaloro, A. Oriani, A. Della Volpe, C. Boschetti, A. Cortelezzi, A. T. Maiolo

Research output: Contribution to journalArticle

Abstract

Sixty-three non randomized adults with acute myelogenous leukemia were treated with an idarubicin-based protocol. The patients achieving complete remission received autologous bone marrow transplantation or (if >50 years or refusing autologous bone marrow transplantation) high-dose Ara-C, as late intensification. Fifty-two patients (82.5%) achieved complete remission, 45 after one induction course and 16 of them underwent autologous bone marrow transplantation a median of 11 months later. As of December 1997 (median follow-up 112 months, range 50-135 months), 16 patients were still in complete remission (10 after autologous bone marrow transplantation, 6 after high-dose Ara-C) and 29 had relapsed (median time to relapse 14 months, range 2-75 months). Four patients died in complete remission. The median disease- free survival was 25 months; the 50-month and 10-year disease-free survival were 41% and 35% respectively. No significant differences were observed between the autologous bone marrow transplantation and high-dose Ara-C treated patients whose complete remission had lasted more than 11 months. The median disease-free survival in the autografted patients had not been reached after 120 months (the 50-month and 10-year disease-free survival chances were both 67%). Age was the only predictive variable for leukemic relapse. These long-term results confirm the antileukemic efficacy of an idarubicin- containing protocol, which led to high complete remission rates and favorably influenced disease-free survival. Furthermore, the efficacy of late intensification treatment with either autologous bone marrow transplantation or high-dose Ara-C is underscored. The disease-free survival chances after autologous bone marrow transplantation are comparable with those published for allogeneic bone marrow transplantation; however, disease-free survival of the patients receiving a high-dose Ara-C intensification regimen is not significantly worse than that seen after autologous bone marrow transplantation.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalAnnali Italiani di Medicina Interna
Volume13
Issue number3
Publication statusPublished - 1998

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Acute Myeloid Leukemia
Disease-Free Survival
Cytarabine
Idarubicin
Recurrence
Homologous Transplantation

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Long-term results in non randomized patients with acute myelogenous leukemia : A single institution experience. / Deliliers, G. L.; Annaloro, C.; Oriani, A.; Della Volpe, A.; Boschetti, C.; Cortelezzi, A.; Maiolo, A. T.

In: Annali Italiani di Medicina Interna, Vol. 13, No. 3, 1998, p. 146-151.

Research output: Contribution to journalArticle

Deliliers, G. L. ; Annaloro, C. ; Oriani, A. ; Della Volpe, A. ; Boschetti, C. ; Cortelezzi, A. ; Maiolo, A. T. / Long-term results in non randomized patients with acute myelogenous leukemia : A single institution experience. In: Annali Italiani di Medicina Interna. 1998 ; Vol. 13, No. 3. pp. 146-151.
@article{91fab9b1078a4c788b1c5d4d7680ff14,
title = "Long-term results in non randomized patients with acute myelogenous leukemia: A single institution experience",
abstract = "Sixty-three non randomized adults with acute myelogenous leukemia were treated with an idarubicin-based protocol. The patients achieving complete remission received autologous bone marrow transplantation or (if >50 years or refusing autologous bone marrow transplantation) high-dose Ara-C, as late intensification. Fifty-two patients (82.5{\%}) achieved complete remission, 45 after one induction course and 16 of them underwent autologous bone marrow transplantation a median of 11 months later. As of December 1997 (median follow-up 112 months, range 50-135 months), 16 patients were still in complete remission (10 after autologous bone marrow transplantation, 6 after high-dose Ara-C) and 29 had relapsed (median time to relapse 14 months, range 2-75 months). Four patients died in complete remission. The median disease- free survival was 25 months; the 50-month and 10-year disease-free survival were 41{\%} and 35{\%} respectively. No significant differences were observed between the autologous bone marrow transplantation and high-dose Ara-C treated patients whose complete remission had lasted more than 11 months. The median disease-free survival in the autografted patients had not been reached after 120 months (the 50-month and 10-year disease-free survival chances were both 67{\%}). Age was the only predictive variable for leukemic relapse. These long-term results confirm the antileukemic efficacy of an idarubicin- containing protocol, which led to high complete remission rates and favorably influenced disease-free survival. Furthermore, the efficacy of late intensification treatment with either autologous bone marrow transplantation or high-dose Ara-C is underscored. The disease-free survival chances after autologous bone marrow transplantation are comparable with those published for allogeneic bone marrow transplantation; however, disease-free survival of the patients receiving a high-dose Ara-C intensification regimen is not significantly worse than that seen after autologous bone marrow transplantation.",
author = "Deliliers, {G. L.} and C. Annaloro and A. Oriani and {Della Volpe}, A. and C. Boschetti and A. Cortelezzi and Maiolo, {A. T.}",
year = "1998",
language = "English",
volume = "13",
pages = "146--151",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",
number = "3",

}

TY - JOUR

T1 - Long-term results in non randomized patients with acute myelogenous leukemia

T2 - A single institution experience

AU - Deliliers, G. L.

AU - Annaloro, C.

AU - Oriani, A.

AU - Della Volpe, A.

AU - Boschetti, C.

AU - Cortelezzi, A.

AU - Maiolo, A. T.

PY - 1998

Y1 - 1998

N2 - Sixty-three non randomized adults with acute myelogenous leukemia were treated with an idarubicin-based protocol. The patients achieving complete remission received autologous bone marrow transplantation or (if >50 years or refusing autologous bone marrow transplantation) high-dose Ara-C, as late intensification. Fifty-two patients (82.5%) achieved complete remission, 45 after one induction course and 16 of them underwent autologous bone marrow transplantation a median of 11 months later. As of December 1997 (median follow-up 112 months, range 50-135 months), 16 patients were still in complete remission (10 after autologous bone marrow transplantation, 6 after high-dose Ara-C) and 29 had relapsed (median time to relapse 14 months, range 2-75 months). Four patients died in complete remission. The median disease- free survival was 25 months; the 50-month and 10-year disease-free survival were 41% and 35% respectively. No significant differences were observed between the autologous bone marrow transplantation and high-dose Ara-C treated patients whose complete remission had lasted more than 11 months. The median disease-free survival in the autografted patients had not been reached after 120 months (the 50-month and 10-year disease-free survival chances were both 67%). Age was the only predictive variable for leukemic relapse. These long-term results confirm the antileukemic efficacy of an idarubicin- containing protocol, which led to high complete remission rates and favorably influenced disease-free survival. Furthermore, the efficacy of late intensification treatment with either autologous bone marrow transplantation or high-dose Ara-C is underscored. The disease-free survival chances after autologous bone marrow transplantation are comparable with those published for allogeneic bone marrow transplantation; however, disease-free survival of the patients receiving a high-dose Ara-C intensification regimen is not significantly worse than that seen after autologous bone marrow transplantation.

AB - Sixty-three non randomized adults with acute myelogenous leukemia were treated with an idarubicin-based protocol. The patients achieving complete remission received autologous bone marrow transplantation or (if >50 years or refusing autologous bone marrow transplantation) high-dose Ara-C, as late intensification. Fifty-two patients (82.5%) achieved complete remission, 45 after one induction course and 16 of them underwent autologous bone marrow transplantation a median of 11 months later. As of December 1997 (median follow-up 112 months, range 50-135 months), 16 patients were still in complete remission (10 after autologous bone marrow transplantation, 6 after high-dose Ara-C) and 29 had relapsed (median time to relapse 14 months, range 2-75 months). Four patients died in complete remission. The median disease- free survival was 25 months; the 50-month and 10-year disease-free survival were 41% and 35% respectively. No significant differences were observed between the autologous bone marrow transplantation and high-dose Ara-C treated patients whose complete remission had lasted more than 11 months. The median disease-free survival in the autografted patients had not been reached after 120 months (the 50-month and 10-year disease-free survival chances were both 67%). Age was the only predictive variable for leukemic relapse. These long-term results confirm the antileukemic efficacy of an idarubicin- containing protocol, which led to high complete remission rates and favorably influenced disease-free survival. Furthermore, the efficacy of late intensification treatment with either autologous bone marrow transplantation or high-dose Ara-C is underscored. The disease-free survival chances after autologous bone marrow transplantation are comparable with those published for allogeneic bone marrow transplantation; however, disease-free survival of the patients receiving a high-dose Ara-C intensification regimen is not significantly worse than that seen after autologous bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0031755166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031755166&partnerID=8YFLogxK

M3 - Article

C2 - 9859570

AN - SCOPUS:0031755166

VL - 13

SP - 146

EP - 151

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

IS - 3

ER -